Drug Trial Radar · NCT03700242
Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year
Last checked: Nov 19, 2026Latest source record: Apr 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
570
Actual
Start
Sep 26, 2018
Primary completion
Jan 19, 2019
Study completion Apr 8, 2020
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Oct 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is to demonstrate that a short intramuscular (IM) pre-exposure prophylaxis (PrEP) regimen is non-inferior to the reference IM PrEP regimen in terms of seroconversion rate. The secondary objectives of the study are: * To describe the immunogenicity of the PrEP regimen in each group * To describe the antibody persistence in each group 6 months and 1 year after the last PrEP vaccination * To describe the immunogenicity of the simulated post-exposure prophylaxis (PEP) regimen in each group * To describe the safety profile of study vaccines administered as PrEP regimen and as a simulated PEP regimen in each group
Conditions
- Healthy Volunteers (Rabies Immunization)
Interventions
HDCVBiological
Pharmaceutical form:Solution for injection Route of administration: Intramuscular
HDCVBiological
Pharmaceutical form:Solution for injection Route of administration: Intradermal
PVRVBiological
Pharmaceutical form:Solution for injection Route of administration: Intramuscular
PVRVBiological
Pharmaceutical form:Solution for injection Route of administration: Intradermal
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seroconversion of participantTime frame: 14 days after the last PrEP vaccination
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number 002
Cebu City, Philippines
Investigational Site Number 001
City of Muntinlupa, Philippines
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.